GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Honz Pharmaceutical Co 300086.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.80

-0.62%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥466.1m

FY2016FY2025

Net income

−CN¥230.1m

FY2016FY2025

Free cash flow

CN¥29.1m

FY2016FY2025

Shareholders' equity

CN¥899.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥466.1mCN¥472.8mCN¥739.6mCN¥535.7mCN¥836.6mCN¥921.6mCN¥1.01bnCN¥882.7mCN¥668.1mCN¥471.5m
Gross profitCN¥252.6mCN¥247.5mCN¥441.3mCN¥266.4mCN¥418.2mCN¥469.7mCN¥474.2mCN¥389.7mCN¥275.6mCN¥193.6m
Research and developmentCN¥19.1mCN¥19.1mCN¥18.7mCN¥28.4mCN¥14.7mCN¥16.6mCN¥17.2mCN¥28.0mCN¥9.1mCN¥12.3m
Operating income—−CN¥211.4mCN¥25.0m−CN¥194.1mCN¥21.4mCN¥58.0m−CN¥19.1mCN¥42.2mCN¥67.4mCN¥50.7m
Net income−CN¥230.1m−CN¥216.2mCN¥11.5m−CN¥187.6mCN¥11.0mCN¥9.3m−CN¥26.5mCN¥13.4mCN¥55.5mCN¥46.2m
Diluted earnings per share-0.51-0.470.03-0.420.020.02-0.060.030.120.10

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥1.79bnCN¥1.98bnCN¥2.17bnCN¥2.29bnCN¥2.46bnCN¥2.61bnCN¥2.19bnCN¥2.18bnCN¥2.24bnCN¥2.19bn
Cash and short-term investments—CN¥113.2mCN¥144.4mCN¥269.8mCN¥258.6mCN¥258.3mCN¥186.1mCN¥84.2mCN¥132.5mCN¥193.5m
Total liabilitiesCN¥869.8mCN¥810.5mCN¥787.6mCN¥933.0mCN¥905.1mCN¥1.01bnCN¥592.6mCN¥526.9mCN¥315.3mCN¥316.8m
DebtCN¥181.8mCN¥399.7mCN¥501.6mCN¥583.1mCN¥592.8mCN¥648.5mCN¥238.9mCN¥209.5mCN¥100.0mCN¥100.0m
Shareholders' equityCN¥899.7mCN¥1.14bnCN¥1.34bnCN¥1.32bnCN¥1.50bnCN¥1.50bnCN¥1.50bnCN¥1.54bnCN¥1.85bnCN¥1.80bn
Shares outstanding455m461m450m450m452m434m456m450m450m450m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥121.2mCN¥71.5mCN¥70.7mCN¥29.3mCN¥11.3m−CN¥16.7mCN¥45.1mCN¥157.7mCN¥18.2mCN¥90.9m
Capital spending−CN¥92.1m−CN¥92.5m−CN¥137.6m−CN¥45.1m−CN¥220.0m−CN¥299.6m−CN¥131.0m−CN¥291.7m−CN¥152.9m−CN¥41.6m
Free cash flowCN¥29.1m−CN¥21.0m−CN¥66.9m−CN¥15.8m−CN¥208.6m−CN¥316.3m−CN¥85.9m−CN¥134.0m−CN¥134.7mCN¥49.3m
Dividends paid−CN¥16.5m−CN¥19.9m−CN¥24.3m−CN¥26.5m−CN¥40.7m−CN¥22.6m−CN¥67.5m−CN¥9.7m−CN¥3.0m−CN¥4.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥48.3mCN¥96.6mCN¥139.7mCN¥93.9mCN¥120.0mCN¥112.4mCN¥109.0mCN¥143.6m
Gross profitCN¥20.8mCN¥58.5mCN¥78.5mCN¥51.9mCN¥64.7mCN¥57.6mCN¥53.0mCN¥75.8m
Operating income−CN¥16.4m−CN¥4.2m−CN¥50.1m−CN¥51.2m−CN¥47.0m−CN¥5.5m−CN¥82.6m−CN¥19.1m
Net income−CN¥21.0m−CN¥11.7m−CN¥133.5m−CN¥42.5m−CN¥44.4m−CN¥9.7m−CN¥93.5m−CN¥21.9m
Diluted earnings per share-0.05-0.03-0.29-0.09-0.10-0.02-0.20-0.05
Cash from operations———−CN¥9.0mCN¥25.0mCN¥40.0m—CN¥6.0m
Capital spending−CN¥1.0m−CN¥3.0m−CN¥8.0m−CN¥5.0m−CN¥4.0m−CN¥73.0m−CN¥24.0m−CN¥21.0m
Free cash flow———−CN¥14.0mCN¥21.0m−CN¥33.0m—−CN¥15.0m
Total assetsCN¥1.71bnCN¥1.74bnCN¥1.79bnCN¥1.88bnCN¥1.90bnCN¥2.01bnCN¥1.98bnCN¥2.09bn
Cash and short-term investments———CN¥18.0mCN¥47.5mCN¥93.0mCN¥113.2mCN¥123.6m
DebtCN¥153.6mCN¥181.8mCN¥181.8mCN¥234.0mCN¥357.9mCN¥400.4mCN¥381.1mCN¥447.3m
Shareholders' equityCN¥866.9mCN¥887.9mCN¥899.7mCN¥1.05bnCN¥1.09bnCN¥1.13bnCN¥1.14bnCN¥1.25bn

Financial ratios

Data as of 20 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin54.2%52.3%59.7%49.7%50.0%51.0%
Operating margin-51.8%-44.5%6.6%-36.2%4.8%5.2%
Net margin-49.4%-45.7%1.6%-35.0%1.3%1.0%
Return on equity-25.6%-19.0%0.9%-14.3%0.7%0.6%
Return on assets-12.8%-10.9%0.5%-8.2%0.4%0.4%
Free cash flow yield9.3%7.1%9.2%3.3%10.2%12.9%
Revenue growth-1.4%-36.1%38.0%-36.0%-9.2%-8.6%
Earnings growth6.4%-1975.2%-106.1%-1807.3%17.6%-135.3%
Current ratio0.52x0.89x1.60x1.33x1.48x1.22x
Debt to equity0.20x0.33x0.37x0.44x0.39x0.43x
Equity ratio50.2%57.7%62.1%57.5%61.2%57.5%
Interest coverage-13.52x-9.86x1.92x-7.08x2.04x2.48x
R&D as a share of sales4.1%4.0%2.5%5.3%1.8%1.8%
Buybacks as a share of market value1.3%-2.3%-0.0%0.4%-4.1%4.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.5%-12.7%1.3%
Net income7.1%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin53.3%54.5%52.8%49.0%
Net margin-47.5%-28.1%-15.2%-6.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-23.8-10.4229.1-14.9357.0261.1-90.7201.987.5135.6
Price to sales11.74.83.65.24.72.62.43.17.313.3

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 13 Aug 2021.

FY2021FY2019FY2015FY2014FY2013FY2011
Paid in the year0.020.150.0670.0890.1780.133
  • 3-for-2 split · 30 Sept 2015
  • 3-for-2 split · 23 May 2014
  • 2-for-1 split · 18 Apr 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.